Copyright ©The Author(s) 2015.
World J Hematol. Aug 6, 2015; 4(3): 16-53
Published online Aug 6, 2015. doi: 10.5315/wjh.v4.i3.16
Figure 9
Figure 9 Prodromal polycythemia vera with normal red cell mass (red cell mass, Tables 3 and 7) and erythrocytes (< 6 × 1012/L, Tables 8 and 9), prefibrotic idiopathic erythrocythemia and polycythemia vera with increased erythrocytes (> 6 × 1012/L) and red cell mass, and evolution into masked PV with splenoegaly, spent phase polycythemia vera with myelofibrosis (Table 12) and post-polycythemia vera-myelofibrosis according to European Clinical and Pathological criteria defined by Michiels and Thiele ( and according to the 2006-2007 World Health Organization-European Clinical Molecular and Pathological criteria for JAK2 mutated stages of prodromal overt and advanced polycythemia vera[71-73].